Research analysts at Jefferies Group lowered their target price on shares of GlaxoSmithKline (LON:GSK) from GBX 1,750 ($28.71) to GBX 1,650 ($27.07) in a report released on Wednesday, Analyst Ratings Network.com reports. The firm currently has a “hold” rating on the stock. Jefferies Group’s target price suggests a potential upside of 1.23% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday. They now have a GBX 1,810 ($29.70) price target on the stock. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, February 6th. They now have a GBX 1,750 ($28.71) price target on the stock. Finally, analysts at UBS AG reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, February 6th. They now have a GBX 1,650 ($27.07) price target on the stock. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and an average target price of GBX 1,716.19 ($28.16).
GlaxoSmithKline (LON:GSK) opened at 1643.00 on Wednesday. GlaxoSmithKline has a 52 week low of GBX 1444.50 and a 52 week high of GBX 1816.00. The stock has a 50-day moving average of GBX 1606. and a 200-day moving average of GBX 1617.. The company’s market cap is £78.716 billion.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.